Biosimilars are drugs approved by the U.S. Food and Drug Administration (FDA) based on the agency's rigorous standards for safety, effectiveness, and purity. While these innovative, cost-effective treatments have the potential to make a significant difference in patients' lives, lawmakers have failed to act to expand access to biosimilars for the patients who need them most.
Congressional inaction on innovative and affordable biosimilars is unacceptable.
An anti-competitive drug marketplace has kept these life-saving drugs away from the patients who need them the most. We need to change that by calling for policies that support the use of effective, FDA-approved therapies that often cost less than the biologic alternative.
Policies aimed at helping to increase the use of biosimilars will provide patients with access to treatments that are not only proven effective, but that are on average one-third less expensive than similar drugs.
We need policymakers to free up the marketplace to make more affordable treatments for cancer, diabetes,
Sign our action today calling on Congress to accelerate the approval and availability of biosimilar therapies!
Every day, people with chronic and complex conditions are making difficult choices to make ends meet.
The lack of access to safe and effective biosimilar drugs that provide cost advantages over other therapies unnecessarily increases the financial burden on many of the most vulnerable members of our society. According to some estimates, biosimilar drugs currently on the market could save the U.S. as much as $54 billion over the next decade.
You and your colleagues in Congress have the power to change that by easing restrictions that block these affordable drugs from reaching patients.
Expanding access to biosimilars can open up market competition in the healthcare industry, potentially drive down healthcare costs, and alleviate the burden on some of the patients who need them most.
As a concerned constituent, I'm asking you to do something about this. We cannot wait any longer. I urge you to take the lead in passing legislation to open access to biosimilar products. Save patients and taxpayers alike billions.
Thank you for your consideration.
[Your comment here]
[Your name here]